(Reuters) – The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie’s hepatitis C drug Exviera at the request of the company.
The regulator said it withdrew authorisation for the drug on Sept. 25. It added that the authorisation holder, listed as AbbVie Deutschland GmbH & Co. KG, had informed the European Commission of its decision to “permanently discontinue the marketing of the product for commercial reasons.”
Abbvie did not immediately respond to a Reuters request for comment.
The drug, also known as dasabuvir, was granted authorisation in the European Union in January 2015 for the treatment of chronic hepatitis C, a liver disease caused by a bloodborne virus.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
